Publications by authors named "Michael Sheaff"

Claim this Profile
A
A Massive Haemothorax Due to Pleural Extramedullary Haematopoiesis in a Patient With Myelodysplastic Syndrome/Myeloproliferative Neoplasm.
Maha Theeb, Sarah Idris, Michael Sheaff, Kayleigh McCloskey

Cureus· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of a national digital pre-implantation biopsy service for deceased-donor kidney transplantation in the UK (Pithia trial); a stepped-wedge cluster randomised registry trial.
Dominic M Summers, John O O Ayorinde, Desley A Neil, Karla Hemming, Laura Smith, Michael Sheaff

Lancet Reg Health Eur· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An International Collaborative for Reporting Lung Cytopathology.
Michael Sheaff, Philippe Vielh, Deepali Jain

Cytopathology· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Donor-derived membranous nephropathy.
Ramyangshu Chakraborty, Michael Sheaff, Muhammad Magdi Yaqoob

Clin Kidney J· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relapsing ANCA-associated vasculitis presenting as a mediastinal mass.
Christopher Pieri, Benjamin Challoner, Konstantinos Giaslakiotis, Mark Hawthorne, Michael Sheaff

BMJ Case Rep· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Guidelines for Pathologic Diagnosis of Mesothelioma: 2023 Update of the Consensus Statement From the International Mesothelioma Interest Group.
Aliya N Husain, David B Chapel, Richard Attanoos, Mary Beth Beasley, Luka Brcic, Michael Sheaff

Arch Pathol Lab Med· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Renal Transplant Outcomes in Plasma Cell Dyscrasias and AL Amyloidosis after Treatment with Daratumumab.
Barian Mohidin, Amy Needleman, Raymond Fernando, David M Lowe, Ashutosh Wechalekar, Michael Sheaff

J Clin Med· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma: The ATOMIC-Meso Randomized Clinical Trial.
Peter W Szlosarek, Benjamin C Creelan, Thomas Sarkodie, Luke Nolan, Paul Taylor, Michael Sheaff

JAMA Oncol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunoglobulin G4-related disease presenting with nephrotic syndrome due to minimal change disease: a case report.
Amy Needleman, Michael Sheaff, Ruth J Pepper, Rhys D R Evans

J Med Case Rep· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical practice guidelines for the diagnosis and surveillance of BAP1 tumour predisposition syndrome.
Fiona Lalloo, Anju Kulkarni, Cindy Chau, Maartje Nielsen, Michael Sheaff

Eur J Hum Genet· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Perioperative discordance in mesothelioma cell type after pleurectomy/decortication-a possible detrimental effect of neoadjuvant chemotherapy due to epithelial to mesenchymal transition?
Luigi Ventura, Michelle Lee, Ralitsa Baranowski, Joanne Hargrave, Michael Sheaff

Interdiscip Cardiovasc Thorac Surg· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesothelioma.
Melissa M Phillips, Iuliia Pavlyk, Michael Allen, Essam Ghazaly, Rosalind Cutts, Michael Sheaff

Pharmacol Rep· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesothelioma.
Melissa M Phillips, Iuliia Pavlyk, Michael Allen, Essam Ghazaly, Rosalind Cutts, Michael Sheaff

Pharmacol Rep· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BAP1 loss induces mitotic defects in mesothelioma cells through BRCA1-dependent and independent mechanisms.
Anita Singh, Sara Busacca, Aarti Gaba, Michael Sheaff, Charlotte Poile

Oncogene· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Role of 3'-Deoxy-3'-[F] Fluorothymidine Positron Emission Tomography-Computed Tomography as a Predictive Biomarker in Argininosuccinate Synthetase 1-Deficient Thoracic Cancers Treated With Pegargiminase.
Teresa A Szyszko, Joel T Dunn, Melissa M Phillips, John Bomalaski, Michael T Sheaff

JTO Clin Res Rep· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 1 study of ADI-PEG20 (pegargiminase) combined with cisplatin and pemetrexed in ASS1-negative metastatic uveal melanoma.
Pui Ying Chan, Melissa M Phillips, Stephen Ellis, Amanda Johnston, Xiaoxing Feng, Michael T Sheaff

Pigment Cell Melanoma Res· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Progressive hemispheric atrophy in HIV: A Rasmussen's-like variant of CD8 encephalitis?
Maria Thom, Graham Warner, Marie Williamson, Simon Limb, Michael Sheaff

Neuropathol Appl Neurobiol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Active symptom control with or without oral vinorelbine in patients with relapsed malignant pleural mesothelioma (VIM): A randomised, phase 2 trial.
Dean A Fennell, Catharine Porter, Jason Lester, Sarah Danson, Paul Taylor, Michael Sheaff

EClinicalMedicine· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Editorial.
Michael Sheaff, Keith Kerr

Cytopathology· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1, pharmacogenomic, dose-expansion study of pegargiminase plus pemetrexed and cisplatin in patients with ASS1-deficient non-squamous non-small cell lung cancer.
Peter W Szlosarek, Akhila G Wimalasingham, Melissa M Phillips, Peter E Hall, Pui Ying Chan, Michael Sheaff

Cancer Med· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Surgical excision of a rare cardiac tumor: Cardiac hibernoma.
Michelle Lee, Martin T Yates, Alina-Adriana Mistirian, Michael Sheaff, David Lawrence

J Card Surg· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment.
Min Zhang, Jin-Li Luo, Qianqian Sun, James Harber, Alan G Dawson, Michael T Sheaff

Nat Commun· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON study.
Marquita Camilleri, Maria Cuadrado, Elizabeth Phillips, William Wilson, Richard Jenner, Michael Sheaff

Br J Haematol· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment.
Min Zhang, Jin-Li Luo, Qianqian Sun, James Harber, Alan G Dawson, Michael T Sheaff

Nat Commun· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expansion Phase 1 Study of Pegargiminase Plus Pemetrexed and Cisplatin in Patients With Argininosuccinate Synthetase 1-Deficient Mesothelioma: Safety, Efficacy, and Resistance Mechanisms.
Peter W Szlosarek, Melissa M Phillips, Iuliia Pavlyk, Jeremy Steele, Jonathan Shamash, Michael Sheaff

JTO Clin Res Rep· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis